How does HIV persist under antiretroviral therapy: A review of the evidence
2021
HIV-1 is a retrovirus capable of establishing viral reservoirs that remain stable for extended periods under suppressive antiretroviral therapy (ART). Immune dysfunction and latency are well known to contribute to...
Population sizes, HIV prevalence, and HIV prevention among men who paid for sex in sub-Saharan Africa (2000–2020): A meta-analysis of 87 population-based surveys
2022
BACKGROUND: Key populations, including sex workers, are at high risk of HIV acquisition and transmission. Men who pay for sex can contribute to HIV transmission through sexual relationships with both...
A systematic review of linkage-to-care and antiretroviral initiation implementation strategies in low- and middle-income countries across sub-Saharan Africa
2022
Linkage to care (LTC) and initiation of antiretroviral therapy (ART) are key components in the longitudinal care cascade for people living with HIV. Many strategies to optimize these stages of...
Identifying and managing infectious disease syndemics in patients with HIV
2020
PURPOSE OF REVIEW: We will present recent articles focusing on HIV synergistic interactions with other sexually transmitted infections, tuberculosis, and hepatitis, as well as recent advances in the study of...
Shared immunotherapeutic approaches in HIV and hepatitis B virus: Combine and conquer
2020
PURPOSE OF REVIEW: The aim of this study was to identify similarities, differences and lessons to be shared from recent progress in HIV and hepatitis B virus (HBV) immunotherapeutic approaches....
Challenges and opportunities for hepatitis B cure in the setting of HIV–Hepatitis B virus co-infection
2020
PURPOSE OF REVIEW: To examine issues specific to HIV–HBV co-infection that are relevant to the search for and achieving hepatitis B cure in this the setting RECENT FINDINGS: In HIV–HBV...
Recommendations for increasing physician provision of pre-exposure prophylaxis: Implications for medical student training
2021
There is growing evidence that pre-exposure prophylaxis (PrEP) prevents HIV acquisition. However, in the United States, approximately only 4% of people who could benefit from PrEP are currently receiving it,...
Enhancing care for people living with HIV: Current and future monitoring approaches
2021
INTRODUCTION: Antiretroviral therapy (ART) is the most significant advance in the medical management of HIV-1 infection. Given the fact that HIV cannot be eradicated from the body, ART has to...
Adolescents and young adults with early acquired HIV infection in the United States: Unique challenges in treatment and secondary prevention
2021
INTRODUCTION: Worldwide, children who acquired human immunodeficiency virus (HIV) at an early age, either perinatally or through blood transfusion, are reaching adolescence and adulthood due to successful antiretroviral treatment (ART)....
Efavirenz versus protease inhibitors in patients with HIV: A systematic review and meta-analysis
2021
Efavirenz- and protease inhibitor (PI)-based regimens remain viable options across the globe. We conducted a meta-analysis to compare the effectiveness of efavirenz-based regimens relative to PI-based regimens. EMBASE, PubMed, Cochrane,...
Low inducibility of latent human immunodeficiency virus type 1 proviruses as a major barrier to cure
2021
The latent reservoir for human immunodeficiency virus type 1 (HIV-1) in resting CD4+ T cells is a major barrier to cure. The dimensions of the reservoir problem can be defined...
1,2,3-Triazole hybrids with anti-HIV-1 activity
2021
The human immunodeficiency virus type 1 (HIV-1) is the major etiological agent responsible for the acquired immunodeficiency syndrome (AIDS), which is a serious infectious disease and remains one of the...
